Interní Med. 2003; 5(6): 301-307

Existuje efektivní léčba pacientů s refrakterní angínou?

MUDr. Jana Gandalovičová, prof. MUDr. Michael Aschermann DrSc
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Keywords: refractory angina, pharmacotherapy, neuromodulation, laser revascularization, angiogenesis.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gandalovičová J, Aschermann M. Existuje efektivní léčba pacientů s refrakterní angínou? Interní Med. 2003;5(6):301-307.

Refrakterní angína je definována jako přetrvávání anginózních obtíží u pacientů, kde byly vyčerpány dostupné terapeutické metody. Tento stav je svízelnou situací nejen pro pacienta, ale i pro lékaře. Článek shrnuje dosavadní poznatky a možnosti terapie pacientů s refrakterní angínou, uvádí doporučení Evropské kardiologické společnosti ohledně postupů v léčení těchto pacientů.

Does effective therapy exist for patients with refractory angina?

Refractory angina is a chronic condition characterized by presence of angina in patients in whom all conventional therapeutic approaches have failed to control their symptoms. This condition is troublesome not only for a patient, but for a physician as well. The article summarizes current knowledge and therapeutic options of patients with refractory angina, introduces recommendations of European Society of Cardiology regarding evaluation and treatment of these patients.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aschermann M. Biorevaskularizace - naděje pro 21. století? Cor Vasa 1999; 41: 480-482.
    2. Burkhoff D, Schmidt S, et al. The Angina Treatments- Lasers And Normal Therapies In Comparison Investigators (ATLANTIC). Transmyocardial laser revascularization compared with continued medical therapy for reatment of refractory angina pectoris: a prospective randomized trial. Lancet 1999; 354: 885-890. Go to original source... Go to PubMed...
    3. Eliasson T, et al. Treatment guidelines for refractory angina pectoris now available. Therapeutic method varying between behavior therapy and heart transplantation. Lakartidningen 2001; 98: 5170-5174.
    4. Grines CL, Watkins MW, et al. Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris. Circulation 2002; 105: 1291. Go to original source... Go to PubMed...
    5. Hautvast RWM, Brouwer J, et al. Effect of spinal cord stimulation on heart rate variability and myocardial ischemia in patients with chronic intractable angina pectoris: a prospective ambulatory electrocardiiiographic study. Clin cardiol 1998; 21: 33-38. Go to original source... Go to PubMed...
    6. Hendel RC, Henry TD, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101: 118-121. Go to original source... Go to PubMed...
    7. Horvath KA, Cohn LH, et al. Transmyocardial laser revascularization: results of a multicenter trial with transmyocardial laser revascularization as sole therapy for end-stage coronary artery disease. J Thorac Cardiovasc Surg 1997; 113: 645-654. Go to original source... Go to PubMed...
    8. Isner JM, Pieczek A, et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF 165 in patient with ischemic limb. Lancet 1996; 348: 370-374. Go to original source... Go to PubMed...
    9. Kim MC, Kini A, Shara SK. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol 2002; 39: 923-934. Go to original source... Go to PubMed...
    10. Knudson ML, Wyse DG, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. JAMA 2002; 287: 481-486. Go to original source... Go to PubMed...
    11. Latif OA, Nedelkovic SS, et al. Spinal cord stimulation for chronic intractable angina pectoris: a unified theory on its mechaism. Clin Cardiol 2001; 24: 533-541. Go to original source... Go to PubMed...
    12. Leschke M, Schoebel FC, et al. Long-term intermitent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomised dose-response trial. J m Coll Cardiol 1996; 27: 575-584. Go to original source... Go to PubMed...
    13. Losordo DW, Vale PR, et al. Gene therapy for myocardial injection of ph VEGF 165 as a sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804. Go to original source... Go to PubMed...
    14. Louis AA, Manooousos IR, et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ANRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Eur J Heart Fail 2002; 4: 111-116. Go to original source... Go to PubMed...
    15. Mannheimer C, Camici P, et al. The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 2002; 3: 355-370. Go to original source... Go to PubMed...
    16. Mannheimer C, Eliasson T, et al. Electrical stimlation versus coronary artery bypass surgry in severe angina pectoris: the ESBY study. Circulation 1998; 37: 1157-1163. Go to original source... Go to PubMed...
    17. Mitka M. Results of the CURE trial for acute coronary syndrome. JAMA 2001; 285: 1828-1829. Go to original source... Go to PubMed...
    18. Mukherjee D, Bhatt D, et al. Direct myocardial revascularization and angiogenesis: how many patients might be eligible? Am J Cardiol 1999; 84: 598-600. Go to original source... Go to PubMed...
    19. Oesterle SN, Reifart N, et al. Percutanneous in situ coronary venous arterialization: report of the first human catheter based coronary artery bypass. Circulation 2001; 103: 2539-2543. Go to original source... Go to PubMed...
    20. Oesterle SN, Sanborn TA, et al. Percutanneous transmyocardial laser revascularization for severe angina: the Potential Class Improvement From Intramyocardial Channels (PACIFIC) randomized trial. Lancet 2000; 356: 1705-1710. Go to original source... Go to PubMed...
    21. Pitt B, Waters D, et al. Aggresive lipid lowerig therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76. Go to original source... Go to PubMed...
    22. REVACS shows positive results for gene therapy on CAD patients ina randomized trial. HeartWire News; Nov 20, 2002. www.theheart.org
    23. Rosengart TK, Lee LY, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474. Go to original source... Go to PubMed...
    24. Shofield PM, Sharples LD, et al. Transmyocardial laser revascularization in patients with refractory angina: a randomised controlled trial. Lancet 1999; 353: 519-524. Go to original source... Go to PubMed...
    25. Schoebel FC, Leschke M, et al. Chronic intermitent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a pilot study. Clin Cardiol 1996; 19: 115-120. Go to original source... Go to PubMed...
    26. Schumacher B, Pecher P, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-650. Go to original source... Go to PubMed...
    27. The Heart Outcomes Prevention Evaluation Study Ivestigators. Effects of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.